Synergistic use of more innovative therapies such as the poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor Olaparib has been shown to increase sensitivity of tumor cells to PRRT in vitro [143]. Here, PARP1 is linked to neoplasm.